Bone Metabolism Panel

PREVEDIG medical's Bone Metabolism Panel measures all key markers of bone turnover, calcium homeostasis, and Vitamin D status: PTH (1-84), calcitonin, osteocalcin, bone-specific alkaline phosphatase (bone ALP / osteaza), Crosslaps (β-CTX — bone resorption marker), P1NP (bone formation marker), and 25-OH Vitamin D. Together, these seven markers provide a complete metabolic bone profile — identifying osteoporosis risk, Vitamin D deficiency, hyperparathyroidism, Paget's disease, and renal osteodystrophy, and enabling quantitative monitoring of anti-resorptive treatment (bisphosphonates, denosumab) or Vitamin D supplementation. The panel includes both a formation marker (P1NP) and a resorption marker (β-CTX), enabling assessment of whether bone loss or bone gain is currently dominant — information that cannot be obtained from a DEXA scan alone. All markers are analysed at PREVEDIG's ISO 15189-accredited laboratory.

Bone is a dynamic tissue undergoing continuous remodelling — old bone is resorbed by osteoclasts and replaced by new bone formed by osteoblasts. This process accelerates significantly in women post-menopause and declines gradually in men from the mid-40s. PREVEDIG medical's Bone Metabolism Panel assesses the regulatory hormones, formation markers, and resorption markers that together characterise the current state of bone metabolism. **The seven markers explained:** **PTH 1-84 (intact parathyroid hormone)** is the primary regulator of calcium and phosphate homeostasis. PTH rises when serum calcium falls, signalling the kidneys to retain calcium, the gut to absorb more calcium (via Vitamin D activation), and bone to release calcium. Elevated PTH (primary hyperparathyroidism, or secondary hyperparathyroidism from Vitamin D deficiency and renal disease) drives excessive bone resorption and is among the most common endocrine causes of osteoporosis. Suppressed PTH may indicate hypercalcaemia from malignancy or vitamin D toxicity. **Calcitonin** is secreted by thyroid C-cells and opposes PTH by inhibiting osteoclast activity and reducing serum calcium. Significantly elevated calcitonin is the defining marker for medullary thyroid carcinoma — a genetic form of thyroid cancer (MEN2) for which calcitonin screening is recommended in first-degree relatives. Mildly elevated calcitonin may also indicate C-cell hyperplasia. **Osteocalcin** is produced exclusively by osteoblasts during bone formation and is incorporated into the bone matrix. Serum osteocalcin reflects active osteoblast activity and bone formation rate. Elevated osteocalcin is seen in high-turnover states (post-fracture healing, Paget's disease, hyperparathyroidism); it declines with anti-resorptive treatment and in vitamin K deficiency. **Bone-specific alkaline phosphatase (bone ALP / osteaza)** is an isoenzyme produced specifically by osteoblasts, unlike total ALP which also reflects hepatic and intestinal isoenzymes. Bone ALP is a more specific formation marker than total ALP and is the preferred marker for monitoring Paget's disease and metabolic bone disease in patients with co-existing liver disease. **Crosslaps (β-CTX — serum C-terminal telopeptide of type I collagen)** is released into circulation when osteoclasts resorb collagen in bone matrix. β-CTX is the most widely validated and sensitive serum bone resorption marker. β-CTX exhibits diurnal variation and is highest in the morning fasting state — early morning fasting draws are required for reproducible results. β-CTX falls rapidly (within 3 months) with bisphosphonate or denosumab treatment, making it the primary monitoring tool for anti-resorptive therapy. **P1NP (procollagen type I N-terminal propeptide)** is released during the formation of new type I collagen in bone. It is the preferred bone formation marker recommended by the International Osteoporosis Foundation for monitoring anabolic therapies (teriparatide, romosozumab). Unlike osteocalcin, P1NP is more stable and less affected by renal function and vitamin K status. **25-OH Vitamin D (calcidiol)** is the primary storage form of Vitamin D and the most accurate indicator of Vitamin D status. It is produced in the liver from dietary Vitamin D3 (cholecalciferol) and UVB-activated skin Vitamin D and is the form that is measured for clinical assessment. Reference intervals: deficient <50 nmol/L, insufficient 50–75 nmol/L, sufficient 75–200 nmol/L. Czech population studies consistently show >50% of adults are Vitamin D insufficient in winter months. **Morning fasting required:** β-CTX is markedly affected by fasting status and diurnal variation — results are clinically meaningless unless drawn fasted (≥6 hours) in the early morning. **Who benefits:** Women post-menopause, men over 55, patients with osteoporosis or osteopenia on DEXA, individuals on long-term corticosteroids, patients with chronic kidney disease, those with hyperparathyroidism or Vitamin D deficiency, patients on bisphosphonate or denosumab therapy needing treatment response monitoring, individuals with suspected Paget's disease or medullary thyroid cancer.